.Planet Wellness Institution. Weight problems and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Health Condition Risk Factor Collaboration. Worldwide patterns in skinny and also excessive weight coming from 1990 to 2022: a pooled analysis of 3663 population-representative research studies with 222 thousand kids, teens, and also adults. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.International Worry Illness Collaborators. Global, regional, as well as national worry of diabetic issues from 1990 to 2021, along with estimates of incidence to 2050: an organized evaluation for the Global Concern of Ailment Research 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & Planet Renal Day Steering Board. Obesity and also renal illness: concealed outcomes of the wide-ranging. Kidney Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et al.
A systematic evaluation and also meta-analysis recommends excessive weight predicts beginning of persistent renal illness in the standard populace. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google.com Scholaru00c2.Jiang, Z. et cetera. Obesity and also constant renal ailment.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Hall, J. E., carry out Carmo, J. M., da Silva, A.
A., Wang, Z. & Hall, M. E.
Being overweight, renal disorder and high blood pressure: mechanistic hyperlinks. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Kidney Condition: Improving Global Results CKD Work Team.
KDIGO 2024 Scientific Practice Rule for the evaluation and monitoring of chronic kidney ailment. Renal Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google Scholaru00c2.Renal Illness: Improving International Results Diabetes The Office Group. KDIGO 2022 Scientific Method Guideline for diabetic issues administration in constant kidney condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google.com Scholaru00c2.Oshima, M. et al.
Early change in albuminuria with canagliflozin anticipates kidney and also cardio end results: a post hoc evaluation from the CREDENCE test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an intended for renoprotection in people with style 2 diabetic person nephropathy: trainings coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H.
J. et al. Is a decline in albuminuria related to renal and also cardiovascular protection?
A post hoc study of the height trial. Diabetes Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic renal health condition: an evaluation of their kidney as well as heart defense. Are actually.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et al. GLP-1 as well as the renal: from physiology to pharmacology and results in diabetes mellitus.
Nat. Rev. Nephrol.
13, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et al. Semaglutide and also cardio results in clients with style 2 diabetes mellitus. N.
Engl. J. Med.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also heart results in excessive weight without diabetes mellitus. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Perkovic, V. et al.
Impacts of semaglutide on constant kidney illness in people with style 2 diabetic issues. N. Engl.
J. Med. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et cetera.
Long-term kidney outcomes of semaglutide in excessive weight as well as heart attack in the SELECT trial. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Results of semaglutide on albuminuria and renal feature in people with obese or obesity with or even without style 2 diabetic issues: preliminary evaluation coming from the STEP 1, 2, as well as 3 tests.
Diabetes Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Witch Doctor, A. M.
et al. Impact of the glucagon-like peptide-1 receptor agonists semaglutide and also liraglutide on kidney end results in individuals along with kind 2 diabetes mellitus: pooled analysis of SUSTAIN 6 and innovator. Circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et cetera.
Effect of semaglutide on renal function all over different levels of standard HbA1c, blood pressure, physical body weight as well as albuminuria in SUSTAIN 6 and leader 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus insulin glargine in individuals along with type 2 diabetes and moderate-to-severe chronic renal health condition (AWARD-7): a multicentre, open-label, randomised test.
Lancet Diabetic Issues Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Adjustment in albuminuria as a surrogate endpoint for progress of renal disease: a meta-analysis of procedure results in randomised professional tests. Lancet Diabetes Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Mann, J. F. E.
et cetera. Effects of semaglutide along with as well as without associated with SGLT2 prevention make use of in individuals with style 2 diabetes and also constant kidney condition in the circulation test. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et al. Cardiovascular, kidney and also safety and security outcomes with GLP-1 receptor agonists alone as well as in mix with SGLT2 inhibitors in kind 2 diabetes mellitus: a methodical evaluation and also meta-analysis.
Blood circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Efficiency and security of SGLT2 inhibitors along with and also without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised regulated trials. Lancet Diabetes Mellitus Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Effects of tirzepatide versus insulin glargine on renal end results in kind 2 diabetes mellitus in the SURPASS-4 test: post-hoc evaluation of an open-label, randomised, phase 3 test.
Lancet Diabetes Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Tuttle, K.
R. et cetera. Body system weight and also eGFR during dulaglutide treatment in kind 2 diabetic issues and also moderate-to-severe chronic renal condition (AWARD-7).
Diabetes Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Results of tirzepatide versus the hormone insulin glargine on cystatin c-based renal feature: a SURPASS-4 message hoc study. Diabetic issues Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetic Issues Care (American Diabetes mellitus Association, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et al. Results of bariatric surgical treatment on kidney functionality in overweight patients: a step-by-step analysis and also meta analysis.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Bilha, S. C.
et al. The impacts of bariatric surgical treatment on kidney results: a step-by-step review and also meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et al. The assessed glomerular filtration cost (mGFR) prior to as well as 6 months after bariatric surgery: a fly study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google.com Scholaru00c2.Fawaz, S.
et al. Adiponectin lessens glomerular endothelial glycocalyx disruption and also recovers glomerular obstacle feature in a mouse style of kind 2 diabetes. Diabetes 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration pertaining to diabetic issues mellitus as well as excessive weight in human illness. Realm J.
Diabetes Mellitus 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Determining albuminuria in individuals along with excessive weight: difficulties of the urinary system albumin-creatinine proportion. Kidney Medication.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in grownups with overweight or obesity.
N. Engl. J.
Medication. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et cetera. An even more accurate strategy to estimate glomerular purification percentage from serum creatinine: a new forecast formula.
Alteration of Diet in Renal Condition Study Hall. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Stevens, J.
et al. UHPLC-MS/MS technique for iohexol resolve in individual EDTA and lithium-heparin blood, individual urine as well as in goat- and also swine EDTA plasma. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et cetera.
Effectiveness and safety and security of aldosterone synthase inhibition along with and also without empagliflozin for constant kidney illness: a randomised, controlled, stage 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.de Zeeuw, D.
et cetera. Effectiveness of a novel inhibitor of general attachment protein-1 in lowering albuminuria in individuals with diabetic renal condition (ALBUM): a randomised, placebo-controlled, stage 2 trial. Lancet Diabetic Issues Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients along with persistent kidney illness (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, scientific test.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Effect of avenciguat on albuminuria in people with CKD: pair of randomized placebo-controlled trials.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Sparsentan in people with IgA nephropathy: a prespecified interim analysis as a result of a randomised, double-blind, active-controlled scientific test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.